An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Pneumonia is an infection of the lungs that can be caused most commonly by bacteria or viruses, such as Streptococcus ...

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy ...

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung ...

Broad Institute to collaborate on flagship project tapping Illumina's new spatial technology At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning ...

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative ...

Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, ...

An international team of researchers has, for the first time, created a detailed map of the location and identity of individual cells in the adult lung, both from healthy lungs and in lungs from ...